Chemo-free regimens in lymphoma

Loretta Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses chemotherapy-free regimens in lymphoma including lenalidomide based approaches, an oral immune modulator, in follicular lymphoma in combination with rituximab as evaluated in the Phase III RELEVANCE study (NCT01476787). Dr Nastoupil also discusses tazemetostat, an EZH2 inhibitor recently approved by the FDA for patients EZH2 mutation-positive, relapsed, or refractory follicular lymphoma. Lastly, the FDA approval of tafasitamb, a naked CD19 antibody in combination with lenalidomide for relapsed large cell lymphoma is discussed by Dr Nastoupil, which fills an unmet need for these patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).